Q4 Revenue Jumps 20% on Pathology Strength; Radiology Declines
Thyrocare Technologies Limited · THYROCARE · NSE ·
<b>Strong Q4FY26 Results:</b> Consolidated revenue grew 20% YoY to ₹223.9 Cr, while consolidated EBITDA surged 31% YoY. <b>Core Business Growth:</b> The Pathology segment, which forms 94% of revenue, grew 22% YoY, driven by strong performance in the Franchise and Partnership chan…